Z B Li
Biographic Data
| ID | 10242466 |
|---|---|
| NAME | Z B Li |
| GIVEN NAMES | Z B |
| FAMILY NAME | Li |
| SIGNATURE | LI Z B |
| AFFILIATIONS | Vanke (China) |
| ORCID | 0000-0003-0208-9523 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
The cost-effectiveness analysis of single-tablet efavirenz-based regimen among HIV-1 infected adults in China
Introduction: In 2018, the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS recommended the adoption of the efavirenz 400 mg-based TLE (tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV)) regimen as the primary first-line treatment for ART-naive HIV-1 infected adults in China. However, the cost-effectiveness of different TLE treatment strategies remains uncertain. This study aimed to evaluate the cost-effectiveness…
No prominent works on this page.
The cost-effectiveness analysis of single-tablet efavirenz-based regimen among HIV-1 infected adults in China
Introduction: In 2018, the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS recommended the adoption of the efavirenz 400 mg-based TLE (tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV)) regimen as the primary first-line treatment for ART-naive HIV-1 infected adults in China. However, the cost-effectiveness of different TLE treatment strategies remains uncertain. This study aimed to evaluate the cost-effectiveness…
Antiretroviral therapy (1 work) · China (1 work) · Efavirenz (1 work) · Geography (1 work) · HIV Research and Treatment (1 work) · HIV/AIDS drug development and treatment (1 work) · HIV/AIDS Research and Interventions (1 work) · Internal Medicine (1 work) · Medicine (1 work) · Regimen (1 work)